PYPD official logo PYPD
PYPD 1-star rating from Upturn Advisory
PolyPid (PYPD) company logo

PolyPid (PYPD)

PolyPid (PYPD) 1-star rating from Upturn Advisory
$3.97
Last Close (24-hour delay)
Profit since last BUY3.39%
upturn advisory logo
Consider higher Upturn Star rating
BUY since 26 days
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

12/05/2025: PYPD (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

Upturn 1 star rating for performance

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

1 star rating from financial analysts

4 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $12.25

1 Year Target Price $12.25

Analysts Price Target For last 52 week
$12.25 Target price
52w Low $2.3
Current$3.97
52w High $4.05

Analysis of Past Performance

Type Stock
Historic Profit -41.04%
Avg. Invested days 36
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 12/05/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 66.04M USD
Price to earnings Ratio -
1Y Target Price 12.25
Price to earnings Ratio -
1Y Target Price 12.25
Volume (30-day avg) 4
Beta 1.49
52 Weeks Range 2.30 - 4.05
Updated Date 12/7/2025
52 Weeks Range 2.30 - 4.05
Updated Date 12/7/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.81

Earnings Date

Report Date 2025-11-12
When Before Market
Estimate -0.52
Actual -0.37

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -87.91%
Return on Equity (TTM) -390.53%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 51588116
Price to Sales(TTM) -
Enterprise Value 51588116
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.36
Shares Outstanding 16634790
Shares Floating 9872748
Shares Outstanding 16634790
Shares Floating 9872748
Percent Insiders 15.72
Percent Institutions 38.43

Icon representing Upturn AI-generated SWOT analysis summary Upturn AI SWOT

PolyPid

PolyPid(PYPD) company logo displayed in Upturn AI summary

Company Overview

Company history and background logo History and Background

PolyPid Ltd. is an Israeli biopharmaceutical company founded in 2008. It is focused on developing innovative drug delivery technologies to improve the efficacy and safety of existing and novel therapeutics. A significant milestone was the initiation of clinical trials for its lead product candidates.

Company business area logo Core Business Areas

  • Drug Delivery Technologies: PolyPid develops a proprietary platform technology based on short peptide fragments (Pepa'x) that form a unique three-dimensional structure. This structure can encapsulate and protect drugs, enabling controlled and sustained release at the target site. The platform is designed to overcome limitations of traditional drug formulations, such as poor solubility, rapid metabolism, and off-target toxicity.

leadership logo Leadership and Structure

PolyPid's leadership team includes individuals with expertise in pharmaceuticals, clinical development, and business management. Specific details on their current organizational structure are not publicly detailed in a widely accessible format but typically involve departments for research and development, clinical affairs, regulatory affairs, and commercialization.

Top Products and Market Share

Product Key Offerings logo Key Offerings

  • POX-001 (Doxycycline-eluting polymer matrix): POX-001 is a novel drug delivery system designed to deliver doxycycline locally and continuously for an extended period. It is being developed for the treatment of surgical site infections (SSIs) and bone infections. The primary competitor in this specific niche would be other prophylactic antibiotic strategies and topical antimicrobial agents. Market share data for this early-stage product is not yet available.
  • POX-002 (Licogliflozin-loaded polymer matrix): POX-002 is another product candidate utilizing PolyPid's platform, intended for the treatment of diabetic foot ulcers (DFUs). It aims to deliver licogliflozin, a novel anti-inflammatory and pro-healing agent, directly to the ulcer site. Competitors include existing wound care products, advanced wound dressings, and other investigational therapies for DFUs. Market share data is not yet available.

Market Dynamics

industry overview logo Industry Overview

PolyPid operates within the biopharmaceutical and drug delivery industries. These sectors are characterized by high research and development costs, long development cycles, stringent regulatory requirements, and significant market potential driven by unmet medical needs.

Positioning

PolyPid positions itself as a leader in novel drug delivery systems, aiming to enhance the therapeutic profiles of existing and new drugs. Its competitive advantage lies in its proprietary Pepa'x technology, which offers controlled and localized drug release, potentially leading to improved efficacy and reduced side effects compared to systemic administration. The company focuses on specific therapeutic areas with significant unmet needs.

Total Addressable Market (TAM)

The TAM for PolyPid's target markets, such as surgical site infections and diabetic foot ulcers, is substantial. The global market for surgical site infection prevention is valued in billions of dollars, and the diabetic foot ulcer market also represents a multi-billion dollar opportunity. PolyPid is positioned to capture a segment of this TAM with its specialized drug delivery solutions, though its current market share is negligible as its products are still in development.

Upturn SWOT Analysis

Strengths

  • Proprietary drug delivery platform technology (Pepa'x)
  • Potential for improved efficacy and reduced side effects of therapeutics
  • Focus on significant unmet medical needs
  • Experienced management team
  • Favorable clinical trial results for early-stage development

Weaknesses

  • Late-stage clinical trial risks and potential for failure
  • Dependence on successful regulatory approvals
  • Limited product pipeline compared to larger pharmaceutical companies
  • Manufacturing scalability and cost considerations
  • Need for significant capital investment for further development and commercialization

Opportunities

  • Expansion of the drug delivery platform to other therapeutic areas
  • Partnerships and collaborations with larger pharmaceutical companies
  • Addressing the growing problem of antibiotic resistance
  • Increasing demand for advanced wound care solutions
  • Potential for out-licensing or acquisition by larger entities

Threats

  • Failure to demonstrate clinical efficacy or safety in late-stage trials
  • Regulatory hurdles and delays in obtaining approvals
  • Intense competition from established pharmaceutical companies and other drug delivery innovators
  • Reimbursement challenges for novel therapies
  • Economic downturns impacting healthcare spending and investment

Competitors and Market Share

Key competitor logo Key Competitors

  • Ethicon (part of Johnson & Johnson)
  • B. Braun Melsungen AG
  • Medtronic plc
  • Smith+Nephew plc
  • Organogenesis Holdings Inc.

Competitive Landscape

PolyPid faces a competitive landscape with established players in wound care and surgical infection prevention, as well as other biotechs developing novel drug delivery systems. Its advantage lies in its unique peptide-based technology offering sustained local delivery. However, competitors benefit from established brand recognition, extensive distribution networks, and larger R&D budgets. PolyPid's success will depend on demonstrating superior clinical outcomes and securing regulatory approvals.

Growth Trajectory and Initiatives

Historical Growth: PolyPid's historical growth has been characterized by the progression of its drug delivery platform from preclinical research to clinical development. Key milestones have included the initiation and progression of clinical trials for its lead product candidates. Financially, its growth has been through capital raises to fund these R&D efforts.

Future Projections: Future growth projections for PolyPid are highly contingent on the successful outcomes of its ongoing clinical trials, regulatory approvals, and eventual commercialization of its products. Analyst estimates, if available, would focus on potential peak sales of its lead candidates and the success of expanding its platform.

Recent Initiatives: Recent initiatives have likely focused on advancing POX-001 and POX-002 through their respective clinical development pathways, engaging with regulatory bodies, and potentially exploring strategic partnerships or licensing agreements.

Summary

PolyPid is a biopharmaceutical company with a promising drug delivery technology. Its strengths lie in its innovative platform and focus on significant unmet needs. However, it faces substantial risks associated with late-stage clinical trials and regulatory approval. The company needs to successfully navigate these hurdles and secure adequate funding to bring its products to market, while fending off strong competition in the pharmaceutical and medical device sectors.

Similar Stocks

Sources and Disclaimers

Data Sources:

  • Company SEC Filings (10-K, 10-Q)
  • Company Press Releases
  • Industry Analyst Reports
  • Financial News Websites

Disclaimers:

This analysis is based on publicly available information and is intended for informational purposes only. It does not constitute investment advice. Investors should conduct their own due diligence before making any investment decisions. Market share data is an estimation and can vary based on reporting.

Information icon for Upturn AI Summarization accuracy disclaimer AI Summarization is directionally correct and might not be accurate.

Information icon for Upturn AI Summarization data freshness disclaimer Summarized information shown could be a few years old and not current.

Information icon warning about Upturn AI Fundamental Rating based on potentially old data Fundamental Rating based on AI could be based on old data.

Information icon warning about potential inaccuracies or hallucinations in Upturn AI-generated summaries AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About PolyPid

Exchange NASDAQ
Headquaters -
IPO Launch date 2020-06-26
CEO & Director Ms. Dikla Czaczkes Akselbrad
Sector Healthcare
Industry Biotechnology
Full time employees 57
Full time employees 57

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.